var data={"title":"Norepinephrine (noradrenaline): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Norepinephrine (noradrenaline): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6666?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=norepinephrine-noradrenaline-drug-information\" class=\"drug drug_general\">see &quot;Norepinephrine (noradrenaline): Drug information&quot;</a> and <a href=\"topic.htm?path=norepinephrine-noradrenaline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Norepinephrine (noradrenaline): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709175\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Antidote for extravasation ischemia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">To prevent sloughing and necrosis in areas in which extravasation has taken place, the area should be infiltrated as soon as possible with 10 to 15 mL of saline solution containing from 5 to 10 mg of phentolamine, an adrenergic blocking agent. A syringe with a fine hypodermic needle should be used, with the solution being infiltrated liberally throughout the area, which is easily identified by its cold, hard, and pallid appearance. Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours. Therefore, phentolamine should be given as soon as possible after the extravasation is noted.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202403\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Levophed</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202404\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Levophed</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054472\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenergic Agonist Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Alpha-Adrenergic Agonist</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sympathomimetic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021885\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose stated in terms of <b>norepinephrine base</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Septic shock, refractory:</b> Limited data available: Continuous IV infusion: Usual initial dose: 0.05 to 0.1 mcg/kg/minute, titrate to desired effect; usual range: 0.1 to 2 mcg/kg/minute; based on experience in pediatric patients during cardiopulmonary arrest (Fuhrman 2011; PALS [Kleinman 2010]); in a prospective observational study of 22 term neonates (GA: 39.1 &plusmn; 1.7 weeks; birth weight: 3.11 &plusmn; 0.78 kg), norepinephrine was initiated at 0.2 to 0.5 mcg/kg/minute and titrated every 30 minutes until desired effect (target normalized blood pressure); the majority of subjects (n=15) responded to a mean dose of 0.5 &plusmn; 0.4 mcg/kg/minute; reported range: 0.2 to 7.1 mcg/kg/minute; the study also suggests that norepinephrine may improve organ perfusion and function as indicated by increased urine output and decrease in serum lactate concentrations (Tourneux 2008a).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Circulatory failure (pulmonary hypertension, persistent [PPHN] induced); refractory:</b> Very limited data available: GA &gt;35 weeks: Continuous IV infusion: Initial: 0.5 mcg/kg/minute, titrate every 30 minutes until desired effect (target mean systemic arterial pressure); in reported experience, most neonates required doses &le;1 mcg/kg/minute. Dosing based on a prospective observational study of 18 neonates with PPHN induced circulatory failure despite adequate hydration (GA: 37 &plusmn; 3 weeks; birth weight: 2.8 &plusmn; 0.7 kg) also receiving nitric oxide; results showed normalization of systemic arterial pressure with no changes in ventilator rate or pressures, postductal oxygen saturations improved from 89% &plusmn; 2% to 95% &plusmn; 4% (p &lt; 0.05) with a decreased oxygen requirement from 51% &plusmn; 20% to 41% &plusmn; 20% (p &lt; 0.01); reported maximum infusion rate: 3.3 mcg/kg/minute in three subjects (Tourneux 2008b);  based on experience in pediatric patients during cardiopulmonary arrest the usual initial dose is 0.05 to 0.1 mcg/kg/minute; usual range: 0.1 to 2 mcg/k/minute (Fuhrman 2011; PALS [Kleinman 2010])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054466\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=norepinephrine-noradrenaline-drug-information\" class=\"drug drug_general\">see &quot;Norepinephrine (noradrenaline): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dose stated in terms of <b>norepinephrine base</b>. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypotension/shock: </b>Infants, Children, and Adolescents: Continuous IV infusion: Initial: 0.05 to 0.1 mcg/kg/minute, titrate to desired effect; usual maximum dose: 2 mcg/kg/minute (Fuhrman 2011; PALS [Kleinman 2010]; Park 2014). A retrospective, descriptive study in pediatric patients (n=144; median age: 25 months; IQR: 9 to 83 months) receiving norepinephrine for septic shock reported the mean initial dose as  0.5 &plusmn; 0.4 mcg/kg/minute up to a maximum mean dose of 2.5 &plusmn; 2.2 mcg/kg/minute; the maximum individual reported rate: 10.5 mcg/kg/minute (Lampin 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Norepinephrine dosage is stated in terms of <b>norepinephrine base</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypotension/shock:</b> Continuous IV infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 8 to 12 <b>mcg/minute</b>; titrate to desired response. Usual maintenance range: 2 to 4 <b>mcg/minute</b>; dosage range varies greatly depending on clinical situation. If patient remains hypotensive despite large doses, evaluate for occult hypovolemia and provide fluid resuscitation as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ACLS dosing range (weight-based dosing): Post cardiac arrest care: Initial: 0.1 to 0.5 mcg/kg/minute (7 to 35 mcg/minute in a 70 kg patient); titrate to desired response (AHA [Peberdy 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202385\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levophed: 1 mg/mL (4 mL) [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (4 mL); 16 mg/250 mL in Dextrose 5% (250 mL); 16 mg/250 mL in NaCl 0.9% (250 mL); 16 mg/500 mL in NaCl 0.9% (500 mL); 4 mg/250 mL in Dextrose 5% (250 mL); 4 mg/250 mL in NaCl 0.9% (250 mL); 4 mg/500 mL in Dextrose 5% (500 mL); 8 mg/250 mL in Dextrose 5% (250 mL); 8 mg/250 mL in NaCl 0.9% (250 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (4 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.08 mg/10 mL in NaCl 0.9% (10 mL); 0.16 mg/10 mL in NaCl 0.9% (10 mL); 0.8 mg/50 mL in NaCl 0.9% (50 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202371\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054476\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Continuous IV infusion: Administer as a continuous infusion via an infusion pump. Central line administration is preferred; extravasation may cause severe ischemic necrosis. Do not administer sodium bicarbonate (or any alkaline solution) through an IV line containing norepinephrine; inactivation of norepinephrine may occur. </p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Rate of infusion (mL/hour) = dose (mcg/kg/minute) x weight (kg) x 60 minutes/hour divided by the concentration (mcg/mL) </p>\n    <p style=\"text-indent:0em;margin-top:0em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate phentolamine (or alternative) antidote (see Management of Drug Extravasations for more details). Apply dry warm compresses (Hurst 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14473013\" class=\"block uicn drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 10 <b>mcg</b>/mL <b>or</b> 16 <b>mcg</b>/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14473012\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 8 <b>mcg</b>/mL <b>or</b> 16 <b>mcg</b>/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202398\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054475\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of shock which persists after adequate fluid volume replacement; severe hypotension (All indications: FDA approved in adults); has also been used for septic shock and in neonates with persistent pulmonary hypertension (PPHN)-induced circulatory failure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174558\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Levophed may be confused with levofloxacin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202437\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, cardiac arrhythmia, peripheral ischemia (digital)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, transient headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin necrosis (with extravasation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202391\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension from hypovolemia except as an emergency measure to maintain coronary and cerebral perfusion until volume could be replaced; mesenteric or peripheral vascular thrombosis unless it is a lifesaving procedure; during anesthesia with cyclopropane (not available in US) or halothane (not available in US) anesthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for vasopressors is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity can not be ruled out with certainty</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202375\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation; infuse into a large vein if possible. Avoid infusion into leg veins. Monitor IV site closely. <b>[US Boxed Warning]: If extravasation occurs, infiltrate the area with diluted phentolamine (5 to 10 mg in saline) with a fine hypodermic needle. Phentolamine should be administered as soon as possible after extravasation is noted to prevent sloughing /necrosis.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoxia/hypercarbia: Use in patients with profound hypoxia or hypercarbia may produce ventricular tachycardia or fibrillation; use with extreme caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sodium metabisulfite: Product may contain sodium metabisulfite; use caution in patients with asthma or a sulfite allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Administer infusions into a large vein, particularly an antecubital vein; some clinicians have indicated that the femoral vein is also an acceptable route. Avoid catheter tie-in technique, if possible. Avoid leg veins in elderly patients or in those suffering from occlusive disorders (eg, atherosclerosis, arteriosclerosis, diabetic endarteritis, Buerger disease). Gangrene has been reported in a lower extremity when infusions were given in an ankle vein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Assure adequate circulatory volume to minimize need for vasoconstrictors. Avoid hypertension; monitor blood pressure closely and adjust infusion rate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299773\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of COMT</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202380\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12650&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Some beta-adrenoceptor mediated effects of Alpha-/Beta-Agonists (Direct-Acting), including anti-anaphylactic effects of epinephrine, may be diminished by Beta-Blockers. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroprocaine: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: May diminish the therapeutic effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">COMT Inhibitors: May decrease the metabolism of COMT Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droxidopa: Norepinephrine may enhance the hypertensive effect of Droxidopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.<b> Exceptions: </b>Ergoloid Mesylates; Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalational Anesthetics: May enhance the arrhythmogenic effect of Norepinephrine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Norepinephrine may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Norepinephrine.<b> Exceptions: </b>Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Management: Avoid, if possible, the use of direct-acting alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202382\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13376222\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Norepinephrine is an endogenous catecholamine and crosses the placenta (Minzter 2010; Wang 1999). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Appropriate medications should not be withheld due to concerns of fetal teratogenicity. Norepinephrine use during the post-resuscitation phase may be considered; however, the effects of vasoactive medications on the fetus should also be considered. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines (Jeejeebhoy [AHA] 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054471\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure (or mean arterial pressure), heart rate, cardiac output (as appropriate), intravascular volume status, pulmonary capillary wedge pressure (as appropriate); urine output, peripheral perfusion; monitor infusion site closely   </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Consult individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202374\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates beta<sub>1</sub>-adrenergic receptors and alpha-adrenergic receptors causing increased contractility and heart rate as well as vasoconstriction, thereby increasing systemic blood pressure and coronary blood flow; clinically, alpha effects (vasoconstriction) are greater than beta effects (inotropic and chronotropic effects)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202390\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Very rapid acting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Vasopressor: 1 to 2 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Via catechol-o-methyltransferase (COMT) and monoamine oxidase (MAO) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as inactive metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323542\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Levophed Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (4 mL): $23.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Norepinephrine Bitartrate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (4 mL): $4.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Norepinephrine-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4MG/250ML 5% (250 mL): $25.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4MG/500ML 5% (500 mL): $31.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8MG/250ML 5% (250 mL): $35.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">16MG/250ML 5% (250 mL): $58.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Norepinephrine-Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4MG/250ML 0.9% (250 mL): $26.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8MG/250ML 0.9% (250 mL): $38.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">16 mg/500 mL 0.9% (500 mL): $74.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">16MG/250ML 0.9% (250 mL): $57.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Norepinephrine-Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.08MG/10ML 0.9% (10 mL): $12.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.16MG/10ML 0.9% (10 mL): $11.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.8 mg/50 mL 0.9% (50 mL): $17.47</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038708\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adine (CL);</li>\n      <li>Adrenor (IN);</li>\n      <li>Arespin (ID);</li>\n      <li>Arterenol (DE);</li>\n      <li>Cardiamed (MY);</li>\n      <li>Efrinalin (BR);</li>\n      <li>Fioritina (AR);</li>\n      <li>Levonor (PL, PY, UY, VN);</li>\n      <li>Levophed (GB, IE, LU);</li>\n      <li>Levophed Bitartrate (AE, AU, BE, BH, CY, EG, GR, IL, IQ, IR, JO, KR, KW, LB, LY, MY, NZ, OM, PH, QA, SA, SG, SY, TH, TW, YE);</li>\n      <li>Mephrin (PH);</li>\n      <li>N-Epi (TH);</li>\n      <li>Nodresol (LK);</li>\n      <li>Norad (LK);</li>\n      <li>Noradrenalina Tartrato (IT);</li>\n      <li>Noradrenaline (GB);</li>\n      <li>Noradrenaline Aguettant (FR);</li>\n      <li>Norages (ES);</li>\n      <li>Noralin (LK);</li>\n      <li>Norene (TH);</li>\n      <li>Norepin (PH);</li>\n      <li>Norepine (TW);</li>\n      <li>Norphed (PH);</li>\n      <li>Norpin (KR, TH);</li>\n      <li>Pridam (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Radrenit (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Rhinopront (LU);</li>\n      <li>Tehipren (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Vascon (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Fuhrman B, Zimmerman J, eds. <i>Pediatric Critical Care</i>. 4th ed. Elsevier Health; 2011. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices (ISMP), &quot;Standard Concentrations of Neonatal Drug Infusions,&quot; <i>ISMP</i>, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &quot;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lampin ME, Rousseaux J, Botte A, Sadik A, Cremer R, Leclerc F. Noradrenaline use for septic shock in children: doses, routes of administration and complications. <i>Acta Paediatr</i>. 2012;101(9):e426-430. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/22568565 /pubmed\" target=\"_blank\" id=\"22568565 \">22568565 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levophed (norepinephrine) [prescribing information]. Lake Forest, IL: Hospira, Inc; February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Minzter BH, Johnson RF, Paschall RL, et al, &quot;The Diverse Effects of Vasopressors on the Fetoplacental Circulation of the Dual Perfused Human Placenta,&quot; <i>Anesth Analg</i>, 2010, 110(3):857-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/20032025/pubmed\" target=\"_blank\" id=\"20032025\">20032025</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peberdy MA, Callaway CW, Neumar RW, et al. Part 9: post-cardiac arrest care: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010;122(18 Suppl 3):S768-786<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/20956225 /pubmed\" target=\"_blank\" id=\"20956225 \">20956225 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &quot;Standardizing I.V. Infusion Concentrations: National Survey Results,&quot; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tourneux P, Rakza T, Abazine A, Krim G, Storme L. Noradrenaline for management of septic shock refractory to fluid loading and dopamine or dobutamine in full-term newborn infants. <i>Acta Paediatr</i>. 2008a;97(2):177-180.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/18177443 /pubmed\" target=\"_blank\" id=\"18177443 \">18177443 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tourneux P, Rakza T, Bouissou A, Krim G, Storme L. Pulmonary circulatory effects of norepinephrine in newborn infants with persistent pulmonary hypertension. <i>J Pediatr</i>. 2008b;153(3):345-349. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/18534241/pubmed\" target=\"_blank\" id=\"18534241\">18534241</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tremblay M, Lessard MR, Tr&eacute;panier CA, et al, &quot;Stability of Norepinephrine Infusions Prepared in Dextrose and Normal Saline Solutions,&quot; <i>Can J Anaesth</i>, 2008, 55(3):163-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/18310626/pubmed\" target=\"_blank\" id=\"18310626\">18310626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang L, Zhang W, and Zhao Y, &quot;The Study of Maternal and Fetal Plasma Catecholamines Levels During Pregnancy and Delivery,&quot; <i>J Perinat Med</i>, 1999, 27(3):195-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/10503181/pubmed\" target=\"_blank\" id=\"10503181\">10503181</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12650 Version 117.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709175\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F202403\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F202404\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1054472\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F46021885\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1054466\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F202385\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F202371\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1054476\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Neonatal\" href=\"#F14473013\" class=\"outlineLink\">Usual Infusion Concentrations: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14473012\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F202398\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1054475\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174558\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F202437\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F202391\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F202375\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299773\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F202380\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F202382\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13376222\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1054471\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F202374\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F202390\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323542\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038708\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12650|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=norepinephrine-noradrenaline-drug-information\" class=\"drug drug_general\">Norepinephrine (noradrenaline): Drug information</a></li><li><a href=\"topic.htm?path=norepinephrine-noradrenaline-patient-drug-information\" class=\"drug drug_patient\">Norepinephrine (noradrenaline): Patient drug information</a></li></ul></div></div>","javascript":null}